期刊文献+

HGF及其c-MET受体在非小细胞肺癌中的研究进展 被引量:12

Research Progress on HGF and c-MET Receptor in Nonsmall Cell Lung Cancer
原文传递
导出
摘要 随着肿瘤分子生物学的飞速发展,分子靶向治疗已成为目前晚期肺癌治疗方法中最具前景的研究领域,因此分子靶点的研究也早已成为医学界关注的热点。近年来,研究发现HGF及其c-MET受体与非小细胞肺癌(non-small cell lung cancer,NSCLC)的发生、发展、组织学类型及预后密切相关。全文就HGF及其c-MET受体的结构、功能及其相关的靶向药物在NSCLC中的研究进展进行综述。 With the rapid development of tumor molecular biology, molecular targeted therapy has been the most promising area of research in the treatment of advanced lung cancer,so molecular targets also has become the focus of attention in the medical profession. In recent years,re- searchers found that HGF and c-MET receptor are associated with the occurrence, development, histological type and prognosis of non-small cell lung cancer(NSCLC). In this paper, the structure, function and correlative targeted drugs of HGF and c-MET receptor in NSCLC were comprehen- sively reviewed.
出处 《中国肿瘤》 CAS 2014年第2期141-147,共7页 China Cancer
基金 国家自然科学基金(81274002)
关键词 HGF C-MET 非小细胞肺癌 靶向治疗 HGF c-MET non-small cell lung cancer targeted therapy
  • 相关文献

参考文献44

  • 1Varughese S,Jahangir KS,Simpson CE,et al. A paradigm shift in the treatment of advanced non-small cell lung can- cer[J]. Am J Med Sci,2012,344(2) : 147-150.
  • 2Siegfried JM,Gubish CT,Rothstein ME,et al. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer [J]. J Thorac Oncol,2012,7 (3) : 485-495.
  • 3D'Areangelo M,Cappuzzo F. Erlotinib in the first-line treatment of non-small-cell lung cancer [J]. Expert Rev Anticancer Ther,2013,13(5):523-533.
  • 4Pao W, Girard N. New driver mutations in non-small-cell lung cancer[J]. Lancet Oncol, 2011,12(2) : 175-180.
  • 5Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats [J]. Biochem Biophys Res Commun, 1984, 122(3): 1450-1459.
  • 6Radtke S,Milanovic M,Ross6 C,et al. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines [J]. J Cell Sci,2013,126(11): 2381-2391.
  • 7Yano S,Yamada T,Takeuchi S,et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrin- sic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort [J].J Thorac Oncol, 2011,6 (12) : 2011 - 2017.
  • 8Gherardi E,Birchmeier W,Birchmeier C,et al. Targeting MET in cancer:rationale and progress [J]. Nat Rev Can- cer, 2012,12(2) : 89-103.
  • 9Ogunwobi OO,Puszyk W,Dong HJ,et al. Epigenetic Up- regulation of HGF and c-MET Drives Metastasis in Hepa- tocellular Carcinoma[J]. PLoS One,2013,8(5):e63765.
  • 10Hage C,Rausch V,Giese N,et al. The novel c-MET in- hibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer [J]. Cell Death Dis, 2013,4e627.

二级参考文献27

  • 1Van Dyke AL, Cote ML, Prysak GM, et al. COX-2/EGFR expression and survival among women with adenocarcinoma of the lung[J]. Carcinogenesis, 2008, 29(9): 1781-7.
  • 2Sasaki H, Shimizu S, Okuda K, et al. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer[J]. Lung Cancer, 2009, 64: 295-300.
  • 3Resniek MB, Routhier J, Konkin T, et al. Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study [J]. Clin Cancer Res, 2004, 10: 3069-75.
  • 4K~ AW, Shi GM, Zhou J, et al. Role of overexpression of CDISI and/or c-Met in predicting prognosis of hepatocellular carcinoma [J]. Hepatology, 2009, 49(2): 491-503.
  • 5Garcia S, Dales JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype[ J]. Hum Pathol, 2007, 38(6): 830-41.
  • 6Sawada K, Radjabi AR, Shinomiy N, et al. e-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion [J]. Cancer Res, 2007, 67(4): 1670-9.
  • 7Okuda K, Sasaki H, Yukiue H, et al. Met gene copy number predicts the prognosis for completely reseeted non-small cell lung cancer[J]. Cancer Sci, 2008, 99(11): 2280-5.
  • 8Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture[J]. Eur J Cancer, 2001, 37(Suppl 8): S4-66.
  • 9Chiang WF, Liu SY, Yen CY, et al. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-assoeiated oral carcinomas [J]. Oral Oncol, 2008, 44: 270-6.
  • 10Airman DG, Lausen B, Sauerbrei W, et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors [J]. J Natl Cancer Inst, 1994, 86: 829-35.

共引文献18

同被引文献148

引证文献12

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部